Appropriateness of array-CGH in the ADHD clinics: A comparative study.

Autor: Baccarin M; Mafalda Luce Center for Pervasive Developmental Disorders, Milan, Italy., Picinelli C; Mafalda Luce Center for Pervasive Developmental Disorders, Milan, Italy., Tomaiuolo P; Mafalda Luce Center for Pervasive Developmental Disorders, Milan, Italy., Castronovo P; Mafalda Luce Center for Pervasive Developmental Disorders, Milan, Italy., Costa A; Service for Neurodevelopmental Disorders, Department of Medicine, University Campus Bio-Medico, Rome, Italy., Verdecchia M; Service for Neurodevelopmental Disorders, Department of Medicine, University Campus Bio-Medico, Rome, Italy., Cannizzaro C; Service for Neurodevelopmental Disorders, Department of Medicine, University Campus Bio-Medico, Rome, Italy., Barbieri G; Service for Neurodevelopmental Disorders, Department of Medicine, University Campus Bio-Medico, Rome, Italy., Sacco R; Service for Neurodevelopmental Disorders, Department of Medicine, University Campus Bio-Medico, Rome, Italy., Persico AM; Interdepartmental Program 'Autism 0-90', 'Gaetano Martino' University Hospital, University of Messina, Messina, Italy., Lintas C; Service for Neurodevelopmental Disorders, Department of Medicine, University Campus Bio-Medico, Rome, Italy.
Jazyk: angličtina
Zdroj: Genes, brain, and behavior [Genes Brain Behav] 2020 Jul; Vol. 19 (6), pp. e12651. Date of Electronic Publication: 2020 Apr 12.
DOI: 10.1111/gbb.12651
Abstrakt: Attention deficit hyperactivity disorder (ADHD) is one of the most common neurodevelopmental disorder with a worldwide prevalence of about 5%. The disorder is characterized by inattentive, hyperactive and impulsive behavior and is often comorbid with other neuropsychiatric conditions. Array comparative genomic hybridization (array-CGH) testing has been proved to be useful to detect chromosomal aberrations in several neuropsychiatric conditions including autism spectrum disorders (ASD) and intellectual disability (ID). The usefulness of array-CGH in the ADHD clinics is still debated and no conclusive evidence has been reached to date. We performed array-CGH in 98 children and adolescents divided in two similarly sized groups according to the clinical diagnosis: (a) one group diagnosed with ADHD as primary diagnosis; (b) the other group in which ADHD was co-morbid with ASD and/or ID. We detected pathogenetic and likely pathogenetic copy number variants (CNVs) in 12% subjects in which ADHD was co-morbid with autism and/or intellectual disability and in 8.5% subjects diagnosed with ADHD as primary diagnosis. Detection of CNVs of unknown clinical significance was similar in the two groups being 27% and 32%, respectively. Benign and likely benign CNVs accounted for 61% and 59.5% in the first and second group, respectively. Differences in the diagnostic yield were not statistically significant between the two groups (P > .05). Our data strongly suggest that array-CGH (a) is a valuable diagnostic tool to detect clinically significant CNVs in individuals with ADHD even in the absence of comorbidity with ASD and/or ID and (b) should be implemented routinely in the ADHD clinics.
(© 2020 John Wiley & Sons Ltd and International Behavioural and Neural Genetics Society.)
Databáze: MEDLINE
Externí odkaz: